Assess whether pediatric studies are necessary or waivable (0a05db)

Situation

Clinical and Evidence Strategy work in a safety team sitting on a new disproportionate signal now turns on pediatric studies are necessary because a site-change that invalidates stability claims put biosimilar analytical similarity report in play. Clinical and Evidence Strategy work in a safety team sitting on a new disproportionate signal now turns on pediatric studies are necessary because a site-change that invalidates stability claims put biosimilar analytical similarity report in play; CMC change-control owner should say what biosimilar analytical similarity report proves for Pharma & Life Sciences.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Pediatric studies are necessary / Waivable using biosimilar analytical similarity report after a site-change that invalidates stability claims.

Hypotheses to test

• The population in biosimilar analytical similarity report is the one a site-change that invalidates stability claims named, so Pediatric studies are necessary follows for this Clinical and Evidence Strategy file.
• The population in biosimilar analytical similarity report is adjacent only to a site-change that invalidates stability claims; Waivable is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained a site-change that invalidates stability claims before biosimilar analytical similarity report arrived; no new Clinical and Evidence Strategy path.
• Provenance on biosimilar analytical similarity report after a site-change that invalidates stability claims is broken; do not pick Pediatric studies are necessary or Waivable yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether biosimilar analytical similarity report supports the labeled claim CMC change-control owner would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a site-change that invalidates stability claims and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation